Precision BioSciences (DTIL)
(Delayed Data from NSDQ)
$9.84 USD
+0.46 (4.90%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $9.83 -0.01 (-0.10%) 5:02 PM ET
2-Buy of 5 2
C Value F Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
DTIL 9.84 +0.46(4.90%)
Will DTIL be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for DTIL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DTIL
Intra-Cellular (ITCI) Moves 23.3% Higher: Will This Strength Last?
Precision BioSciences (DTIL) Now Trades Above Golden Cross: Time to Buy?
DTIL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Predict a 407.94% Upside in Precision BioSciences (DTIL): Here's What You Should Know
Precision BioSciences (DTIL) Soars 13.4%: Is Further Upside Left in the Stock?
Precision BioSciences (DTIL) Reports Q4 Loss, Lags Revenue Estimates
Other News for DTIL
TG Therapeutics: The Cloud Over Briumvi
Buy Rating Affirmed for Precision BioSciences Amid Strong Gene Editing Prospects and Upcoming Milestones
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Precision BioSciences: Strategic Independence and Promising Gene Editing Pipeline Fuel Buy Rating
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics